2. Academic Validation
  3. Loss of Cdkn1a protects against MASLD alone or with alcohol intake by preserving lipid homeostasis

Loss of Cdkn1a protects against MASLD alone or with alcohol intake by preserving lipid homeostasis

  • JHEP Rep. 2024 Oct 5;7(1):101230. doi: 10.1016/j.jhepr.2024.101230.
Arantza Lamas-Paz 1 2,  Alejandro Hionides-Gutiérrez 1,  Feifei Guo 1 3,  Gonzalo Jorquera 4 5,  Laura Morán-Blanco 1,  Raquel Benedé-Ubieto 1,  Mariana Mesquita 1 6,  Olga Estévez-Vázquez 1,  Kang Zheng 1 7,  Marina Mazariegos 1,  Elena Vázquez-Ogando 8 9 10,  Elena Blázquez-López 8 9 10,  Iris Asensio 8 9 10,  Beste Mutlu 11 12,  Beatriz Gomez-Santos 13 14,  María Isabel Peligros 15,  Javier Vaquero 8 9 10,  Rafael Bañares 8 9 10,  Teresa C Delgado 16,  María Luz Martínez-Chantar 10 16,  Eduardo Martínez-Naves 1 2,  Carlos Sanz-García 1,  Mohamed Ramadan Mohamed 17,  Sofía Tesolato 18 19,  Pilar Iniesta 18 19,  Rocío Gallego-Durán 10 20,  Douglas Maya-Miles 10 20,  Javier Ampuero 10 20,  Manuel Romero-Gómez 10 20,  Ana Martínez-Alcocer 10 21,  David Sanfeliu-Redondo 10 21,  Anabel Fernández-Iglesias 10 21,  Jordi Gracia-Sancho 10 21 22,  Mar Coll 10 23,  Isabel Graupera 10 23 24,  Pere Ginès 10 23 24,  Andrea Ciudin 25 26,  Jesús Rivera-Esteban 27 28,  Juan M Pericàs 10 27,  Matías A Ávila 10 29 30,  Maria Dolores Frutos 31,  Carlos Manuel Martínez-Cáceres 32,  Bruno Ramos-Molina 33,  Patricia Aspichueta 10 13 14,  Pere Puigserver 11 12,  Yulia A Nevzorova 1 9 10,  Francisco Javier Cubero 1 9 10
Affiliations

Affiliations

  • 1 Department of Immunology, Ophthalmology and ENT, Complutense University School of Medicine, Madrid, Spain.
  • 2 12 de Octubre Health Research Institute (imas12), Madrid, Spain.
  • 3 Department of Obstetrics and Gynaecology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
  • 4 Institute of Nutrition and Food Technology (INTA), Universidad de Chile, Santiago, Chile.
  • 5 Physiology Institute, Science Faculty, Universidad de Valparaíso, Valparaíso, Chile.
  • 6 State University of Campinas, Campinas, Sao Paulo, Brazil.
  • 7 Department of Anesthesiology, Nanjing Pukou District Hospital of Chinese Medicine Central Laboratory Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
  • 8 Servicio de Aparato Digestivo, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • 9 Health Research Institute Gregorio Marañón (IiSGM), Madrid, Spain.
  • 10 Centre for Biomedical Research, Network on Liver and Digestive Diseases (CIBEREHD), Madrid, Spain.
  • 11 Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • 12 Department of Cell Biology, Harvard Medical School, Boston, MA, USA.
  • 13 Department of Physiology, Basque Country University (UPV/EHU) School of Medicine and Nursing, Bilbao, Spain.
  • 14 Biobizkaia Health Institute, Barakaldo, Spain.
  • 15 Servicio de Anatomía Patológica Hospital General Universitario Gregorio Marañón Madrid, Spain.
  • 16 Liver Disease Laboratory, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Bizkaia, Spain.
  • 17 Department of Internal Medicine III, University Hospital, RWTH Aachen, Aachen, Germany.
  • 18 Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University, Madrid, Spain.
  • 19 San Carlos Health Research Institute (IdISSC), Madrid, Spain.
  • 20 Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
  • 21 Liver Vascular Biology, IDIBAPS Biomedical Research Institute, Barcelona, Spain.
  • 22 Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • 23 Laboratorio de Plasticidad de Células Hepáticas y Reparación de Tejidos, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • 24 Liver Unit, Hospital Clinic, Barcelona, Spain.
  • 25 Endocrinology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute for Research (VHIR), Barcelona, Spain.
  • 26 Centre for Biomedical Research, Network on Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain.
  • 27 Liver Unit, Vall d'Hebron University Hospital, Vall d'Hebron Institute for Research (VHIR), Barcelona, Spain.
  • 28 Puerta de Hierro University Hospital, Instituto de Investigación Sanitaria Puerta de Hierro, Majadahonda, Madrid, Spain.
  • 29 Hepatology Laboratory, Solid Tumors Program, CIMA, University of Navarra, Pamplona, Spain.
  • 30 IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
  • 31 Department of General and Digestive System Surgery, Virgen de la Arrixaca University Hospital, Murcia, Spain.
  • 32 Experimental Pathology Service, Biomedical Research Institute of Murcia (IMIB), Murcia, Spain.
  • 33 Laboratorio de Obesidad y Metabolismo, Instituto de Investigación Biomédica de Murcia (IMIB-Arrixaca), Murcia, Spain.
PMID: 39659733 DOI: 10.1016/j.jhepr.2024.101230
Abstract

Background & aims: Expression of P21, encoded by the CDKN1A gene, has been associated with fibrosis progression in steatotic liver disease (SLD); however, the underlying mechanisms remain unknown. In the present study, we investigated the function of CDKN1A in SLD.

Methods: CDKN1A expression levels were evaluated in different patient cohorts with SLD, fibrosis, and advanced chronic liver disease (ACLD). Cdkn1a -/- and Cdkn1a +/+ mice were fed with either a Western diet (WD), a Lieber-DeCarli (LdC) diet plus multiple EtOH (ethanol) binges, or a DuAL diet (metabolic dysfunction-associated fatty liver disease and alcohol-related liver). Primary hepatocytes were isolated and functional assays performed.

Results: A significant increase in CDKN1A expression was observed in patients with steatohepatitis and fibrosis (with a positive correlation with both NAFLD Activity Score and fibrosis staging scores), cirrhosis and ACLD. Cdkn1a +/+ mice, fed a DuAL diet exhibited liver injury and cell death increased Reactive Oxygen Species (ROS), and markers of senescence (γH2AX, β-GAL, Cdkn1a/p53) contributing to steatosis and inflammation. In contrast, Cdkn1a -/- mutant mice showed a significant decrease in senescence-associated markers as well as in markers of liver injury, hepatic steatosis and an increase in fatty acid oxidation and reduction in free fatty acid uptake as well as de novo lipogenesis. Mechanistically, activation of the AMPK-SIRT3 was observed in Cdkn1a-deleted Animals.

Conclusions: Cdkn1a deletion protected against preclinical SLD by promoting fatty acid oxidation and preventing free fatty acid uptake and de novo lipogenesis via the AMPK-SIRT3 axis. CDKN1A expression was found to be directly correlated with increased severity of NAFLD Activity Score and fibrosis in patients with SLD. CDKN1A could be a potential theragnostic target for the treatment of metabolic dysregulation in patients with SLD, with and without alcohol consumption.

Impact and implications: Expression of p21, encoded by the CDKN1A gene, has been associated with fibrosis progression in steatotic liver disease (SLD), but the molecular mechanisms remain elusive. Interestingly, in this study we found that Cdkn1a deletion protected against preclinical SLD by promoting fatty acid oxidation and preventing free fatty acid uptake and de novo lipogenesis, via the AMPK-SIRT3 axis. Translationally, Cdkn1a expression was found to be directly correlated with increased severity of NAFLD Activity Score (NAS) and fibrosis in SLD patients, and therefore, CDKN1A might be used potential theragnostic target for the treatment of metabolically induced SLD, with and without alcohol consumption.

Keywords

CDKN1A; Hepatocyte; Metabolic dysregulation; Palbociclib; Senescence; Steatotic liver disease (SLD).

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-50767
    99.94%, CDK4/6抑制剂
    CDK
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z